Sam Fazeli

speaker

906 appearances 5 recordings 1 series first heard Oct 2025 last heard 31 Mar

Sam Fazeli’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 5 in all, peaking in Mar 2026 with 2.

newest first · ▶ plays the moment

And then, of course, the competitor drug, Tredelvi, has a different type of side effect, which potentially increases the risk of infections, etc.

So just one quick last comment on this and one last question on Datraway and then we'll move on.

Yeah.

Last question.

What do you think the best partner for a TROP2 ADC is?

I mean, I had a leading question here, but I thought I'd leave that to you to comment.

Yeah.

And of course, my leading question was, is the best combo a PD-1 VEGF or PD-L1 VEGF bispecific?

But I'm going to make a comment and move on to bladder because I'm more interested in your views.

I'm definitely interested in your views on bladder and Matterhorn, Potomac, et cetera.

Sorry, not Matterhorn, Potomac at the conference.

So the problem I have with, everyone's been running around, digging around Harmony 6 trial data.

And of course, when you look at the supplementary details there,

There was a major focus, as there should have been, on excluding patients with a risk of haemoptysis or history of haemoptysis.

And yet, there were some bleeding events on the trial.

So I still am sitting here a little bit worried that this ends up just being a PD-1 plus VEGF.

I don't know.

Actually, do you want to make a comment on that?

Or would you rather not?

Showing 821–840 of 906 · page 42 of 46